X0303 4 2010-10-28 1 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001365618 Hove Anders D C/O VENROCK ASSOCIATES 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 1 0 0 0 Common Stock 2010-10-28 4 D 0 308367 D 0 I By Venrock Partners, L.P. Common Stock 2010-10-28 4 D 0 1512111 D 0 I By Venrock Associates IV, L.P. Common Stock 2010-10-28 4 D 0 37154 D 0 I By Venrock Entrepreneurs Fund IV, L.P. Stock Option (right to purchase) 13.78 2010-10-28 4 D 0 12500 0.00 D 2016-10-24 Common Stock 12500 0 D Stock Option (right to purchase) 19.08 2010-10-28 4 D 0 5000 0.00 D 2017-05-25 Common Stock 5000 0 D Stock Option (right to purchase) 6.63 2010-10-28 4 D 0 5000 0.00 D 2018-05-28 Common Stock 5000 0 D Stock Option (right to purchase) 2.28 2010-10-28 4 D 0 5000 0.00 D 2019-05-27 Common Stock 5000 0 D Stock Option (right to purchase) 3.45 2010-10-28 4 D 0 5000 0.00 D 2020-05-26 Common Stock 5000 0 D Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $420,920.96 cash, (b) 50,603 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 308,367 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Partners, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $2,064,031.52 cash, (b) 248,137 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 1,512,111 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Associates IV, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $50,715.21 cash, (b) 6,097 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 37,154 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Entrepreneurs Fund IV, L.P. is a limited partership, the general partner of which is VEF Management IV, LLC. The reporting person is a member of VEF Management IV, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. This option, which was 100% vested on October 23, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 27, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 15, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 26, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $11,350, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments. This option, which was to be 100% vested on May 25, 2011, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $5,500, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments. /s/ Kathleen Deeley as attorney-in-fact for Anders D. Hove 2010-10-28